Lipid-Lowering Drugs
The British Journal of PsychiatryPublished 1 February 1989Open access
Ian McLoughlin, Philip Clarke
Citations7
SJR quartileQ1
SJR score2.47
SNIP2.17
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is plaus ible that the conversion symptoms may have served as an alternative to a major depressive episode; in other cases (Daniel & Crovitz, 1986) the develop
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Keywords
Medicine
New England Journal of MedicineHelsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
3,875 Citations1987M. H. Frick, Olli Elo +17 more
Results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia.